Latest Car T News

AdAlta’s partner SHcell has gained regulatory approval to provide the BZDS1901 CAR-T therapy to advanced mesothelioma patients in China’s Hainan Boao Lecheng special access zone, marking a key milestone in real-world data collection and treatment availability.

The Star Entertainment Group narrowed its net loss to $307 million in FY26, boosted by refinancing, operational improvements, and a joint venture exit, while navigating ongoing regulatory scrutiny and remediation efforts.

Carma Limited posted a 59% revenue jump to $113.8 million in FY26, doubling gross profit to $10.5 million, while gearing up to double reconditioning capacity and target positive EBITDA in 2027.

Mirrabooka Investments posted a 63.6% profit increase to $13 million for FY26 but saw its portfolio return lag the benchmark. The company declared a 14 cents fully franked dividend and welcomed Alison Gibson as new CEO following Mark Freeman's retirement.

Australian Foundation Investment Company (ASX:AFI) reported a $293.5 million profit for FY26, holding dividends steady despite portfolio returns lagging the market. Leadership transitioned as Alison Gibson took the helm following Mark Freeman’s retirement.

Webjet Group navigated a challenging FY26 with flat OTA revenue and strong EBITDA margins, while its Cars & Motorhomes segment began turning around. The company withheld FY27 earnings guidance, citing ongoing macro uncertainty but noted improved recent trading.

Precinct Properties delivered steady FY26 results marked by record leasing activity, expanded capital partnerships, and a maintained dividend guidance, while advancing key development projects including the Downtown Car Park.

ARB Corporation's FY2026 results show a 3.8% revenue dip and 5.2% profit decline amid challenging 4x4 sales, while international expansion and engineering investment underpin future growth.

Prescient Therapeutics launches a $7 million Share Purchase Plan at an 18.8% discount to fund advancement of its PTX-100 cancer therapy beyond a key 2026 Dose Optimisation Committee review.

Advanced Engineered Materials (ASX:AEM) reported an 85% jump in high purity alumina sales in 1H 2026, with a customer pipeline now valued at US$190 million amid tightening global supply and rising semiconductor industry demand.

Ampol Limited reported a dramatic turnaround with a $1.36 billion statutory profit in H1 2026, buoyed by soaring refinery margins and the strategic acquisition of EG Australia.

AdAlta Limited (ASX:1AD) has progressed its ‘East to West’ cellular immunotherapy strategy by securing its first CAR-T asset, advancing Australian manufacturing and US FDA regulatory engagement, while raising A$5.3 million in FY2026 and reporting a net loss of $4.68 million.